NEUCLONE PTY LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute 2019-05-15 20:13
NeuClone Announces its Sixth Biosimilar Candidate Perjeta(R) (Pertuzumab) for use in Combination Therapy with Herceptin(R) (Trastuzumab) 2018-12-17 21:30
NeuClone Announces First Human Dose of Herceptin® (trastuzumab) Biosimilar Candidate in Phase I Clinical Trial 2018-10-23 21:00
NeuClone Announces Preclinical Results for Stelara® (ustekinumab) Biosimilar Candidate 2018-05-10 20:00
1